Long-lasting impact of the COVID-19 pandemic on incidence and mortality of patients hospitalized for acute heart failure: a nationwide cohort study of the entire French population from 2013 to 2023

Moulaire P*[1], Delory T[1,2,3], Oghina S[4], Damy T[5], Espagnacq M[6], Khlat M[3], Le Cœur S[3], Hejblum G[1], Lapidus N[7]; on behalf of the COVID-HOSP study group

[1]Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, Paris, France
[2]Centre Hospitalier Annecy-Genevois, Epagny Metz-Tessy, France
[3]French Institute for Demographic Studies (INED), Mortality, Health and Epidemiology Unit, Aubervilliers, France
[4]Referral Center for Cardiac Amyloidosis, Mondor Amyloidosis Network, GRC Amyloid Research Institute and Cardiology Department, APHP Henri Mondor Hospital, Créteil, France
[5]Paris-Est Créteil University, INSERM Unit U955, Institut Mondor de Recherche Biomédicale, Clinical Epidemiology and Ageing (CEpiA), Referral Center for Cardiac Amyloidosis, Mondor Amyloidosis Network, GRC Amyloid Research Institute and Cardiology Department, APHP Henri Mondor Hospital, Créteil, France
[6]Institute for Research and Information in Health Economics (IRDES), Paris, France
[7]Sorbonne Université, INSERM, Institut Pierre Louis d'Épidémiologie et de Santé Publique, AP-HP, Hôpital Saint-Antoine, Unité de Santé Publique, Paris, France
*Corresponding author: Paul Moulaire, 27 rue Chaligny, 75012 Paris, France
Email: paul.moulaire@inserm.fr
Institution where the work was performed: INSERM UMRS 1136 Paris

Abstract

Background and aims Healthcare pathways were reorganized in 2020 to manage the COVID-19 pandemic. Despite their urgent status, hospital admissions for acute heart failure (AHF) were reported to decline from 9% to 66% worldwide between 2020 and 2021, with divergent findings on in-hospital mortality. This study aims to describe and interpret the evolution of AHF hospitalizations and in-hospital mortality in France from 2020 to 2023.

Methods Based on the 2.7 million AHF hospitalizations recorded in France (2013–2023), yearly numbers of hospitalizations and deaths expected between 2020 and 2023 were estimated using a Poisson regression model, with 2013–2019 as the reference period. The differences between observed and expected numbers of events were used to quantify the disruptions.

Results A drop in AHF hospitalizations was estimated, starting at 39,271 [38,858; 39,688] (median [interquartile range]) in 2020 and peaking at 51,573 [51,113; 52,030] in 2023, for a total deficit of 168,518 [167,639; 169,408], representing a 15.3% decrease compared to the pre-pandemic trends. An excess in in-hospital mortality was estimated, rising from 827 [726; 928] excess deaths in 2020 to 2,426 [2,324; 2,530] in 2022, before declining to 1,731 [1,624; 1,838] in 2023 representing an increase from 8% to 12% compared to expected values. Both disruptions concerned more females than males. Multifactorial causes contribute to this increasing burden.

Conclusions The apparent long-lasting impact of the COVID-19 pandemic on the management of AHF patients in France, particularly among females, suggests improving the preparedness for future crises, and requires addressing the current sustained disruptions.

Keywords Heart failure, Real world data, Mortality, Hospitalization, COVID-19, Pandemic.

Introduction

At the end of 2019, COVID-19 emerged in Wuhan, China,[1] and by January 30, 2020, the World Health Organization (WHO) declared it a Public Health Emergency of International Concern (PHEIC) due to its rapid global spread.[2] In response to the crisis, many countries implemented unprecedented measures, including lockdowns and significant reorganization of healthcare systems.[3] In France, non-urgent hospitalizations were deferred to mitigate the virus spread and prioritize the care of COVID-19 patients.[4] However, despite the urgent nature of acute heart failure (AHF), a decline in hospitalizations for this condition was observed early in the pandemic period, in March 2020.[5] A decrease in the incidence of AHF hospitalizations, not only in 2020, but also in 2021 and 2022, was highlighted in a more recent study published in 2024, which focused on the epidemiology of hospitalized heart failure in France.[6] However, this latter study considered only the first hospitalization of the year without any prior hospitalizations in the preceding five years and did not provide precise quantification of either the decrease in hospitalizations or in-hospital mortality in the pandemic period. Several studies have reported similar reductions in AHF hospital admissions across Europe[7,8] and worldwide,[9–11] with decreases ranging from 9% to 66% between 2020 and 2021. However, the reported in-hospital mortality of AHF admissions during the pandemic period varied widely, with some studies reporting an increased mortality,[12–14] while others reported no significant change.[15–17] Additionally, little is known about the persistence of the disruptions, including trends in hospitalization rates and mortality in 2023, while the WHO declared the end of the phase of PHEIC on May 5, 2023.[18]

Given the uncertainties regarding the extent of the decline in AHF hospitalizations, the corresponding in-hospital mortality rates, and the evolution of these patterns in 2023, this study aimed to provide a clear understanding of the disruptions during the pandemic period in France. Hospitalization data from 2013 to 2019 were analyzed and used as a reference to model the historical evolution in the numbers of AHF hospitalizations and corresponding in-hospital deaths, allowing for estimates of expected values from 2020 to 2023 in the absence of the pandemic. The primary metrics to assess disruption were the differences between observed and expected hospitalizations and deaths. Our hypothesis posits that the decline in AHF admissions observed during the early phase of the pandemic will likely taper as the pandemic's intensity decreases, potentially with a catch-up phenomenon. By 2023, four years after the pandemic began, we expect to observe a return to the pre-pandemic trend. As for in-hospital mortality, we do not hold a definitive hypothesis. On one hand, hospital admissions may have been restricted to the most severe emergencies, potentially increasing in-hospital mortality. On the other hand, it is possible that more critical patients succumbed to COVID-19, leaving less severe AHF cases, which could lower in-hospital mortality. In any scenario, we expect mortality rates to return, at most, to pre-pandemic levels in 2023.

In summary, the overall objective of this study is to provide a comprehensive overview of the evolution in the management of AHF patients over the past 11 years and to evaluate the full impact of the COVID-19 pandemic period on hospitalizations and associated mortality in France from 2020 to 2023.

Methods

Data sources

Data on hospitalizations for AHF comes from the French Hospital Discharge Database (PMSI), which is part of the National Health Data System (SNDS). The SNDS is a national claims database designed to reimburse care via the French Health Insurance System, covering nearly 100% of the population

receiving healthcare in France.[19] With the growing interest in the scientific medical community for real-world data derived from large administrative healthcare databases, the SNDS has for instance previously been used to study the impact of the pandemic period on acute cardiovascular diseases[20–22] and in other diseases.[23,24] Data on the French population structure were also used in this study and are available in open access from the French National Institute for Statistic and Economic Studies (Insee).[25] There were no missing data for variables used in the study.

Population under study

This open cohort study of the whole French population between January 1, 2013 and December 31, 2023 is reported according to STROBE guidelines[26] (Supplementary Material). As the age structure of the French population is reported on January 1 of each year, the age considered for participants was that on January 1, and data were aggregated by year. Patients aged 99 years or more were handled in a single category. In accordance with the SAGER guidelines[27], sex was always taken into account in the study design and report.

Outcomes of interest

Two outcomes were identified and analyzed during the study period: the annual number of AHF hospitalizations and the number of associated in-hospital deaths. AHF hospitalization events were identified in the SNDS database based on the International Classification of Diseases, 10th Revision (ICD-10), using an algorithm developed by the Healthcare Expenditures and Conditions Mapping[28] (see Supplementary Text 1). In-hospital death was defined as an AHF hospital admission that ended with the death of the patient. Deaths attributed to COVID-19 among patients who died during hospitalization for AHF was assessed in a supplementary analysis (see Supplementary Analysis 1).

Analyzing the evolution of the numbers of AHF hospitalizations and associated in-hospital deaths

To quantify the impact of the pandemic period on the outcomes of interest, we developed a two-step approach comparing the expected and observed numbers of AHF hospitalizations and associated in-hospital deaths. In the first step, the pre-pandemic period (2013 to 2019) was used as a reference to model the natural evolution of both outcomes just before the pandemic onset. The modelling was based on a Poisson regression, detailed in the next subsection. In the second step, for each outcome of interest, the corresponding regression model was used to predict the expected values for years 2020 to 2023, assuming the natural evolution observed during the pre-pandemic period had not been disrupted by the pandemic. The expected values were then compared to the observed occurrences, enabling us to characterize how the natural evolution of AHF hospitalizations and corresponding in-hospital deaths were disrupted following the emergence of the COVID-19 pandemic (see Supplementary Figure 1). Similar models have been widely applied to estimate expected mortality levels for the calculation of cause-specific excess mortality[29] or all-cause excess mortality.[30,31]

Statistical analyses

A Poisson regression model was used to estimate the numbers of expected AHF hospitalizations and in-hospital deaths after the arrival of the pandemic, considering pre-pandemic years 2013−2019 as the reference period.

The model included age as a year-specific categorical variable to accurately capture potential non-linear effects of age on the numbers of hospitalizations and in-hospital deaths, an interaction between age and sex to precisely estimate sex differences across age groups, and calendar year as a numeric variable to assess yearly temporal trends in the numbers of hospitalizations and deaths. To

estimate expected AHF hospitalizations while accounting for changes in population size and age structure over the study period, the natural logarithm of the population was used as an offset term. For in-hospital mortality among AHF admissions, the number of AHF admissions was used as an offset term to account for changes in hospital load over time. The Akaike Information Criterion (AIC) was employed as a selection criterion to optimize goodness-of-fit and avoid overfitting (Supplementary Table 2). To investigate seasonal periodicity, additional analyses were performed at both monthly and weekly temporal resolutions, employing sinusoidal and spline-based models. The details of these models, along with graphical visualizations of the predicted trends and their impact on the final estimates, are available in the Supplementary Material (Supplementary Analysis 2, Supplementary Figures 2 to 4). The Poisson regression used for modelling the number of hospitalizations was:

$$\boldsymbol{log}\left(\widehat{\boldsymbol{eH}}_{\boldsymbol{i,j,k}}\right) = \boldsymbol{log}\left(\boldsymbol{Population}_{\boldsymbol{i,j,k}}\right) + \boldsymbol{\beta}_{\boldsymbol{h}_0} + \boldsymbol{\beta}_{\boldsymbol{h}_1} \cdot \boldsymbol{Sex}_{\boldsymbol{i}} + \boldsymbol{\beta}_{\boldsymbol{h}_2} \cdot \boldsymbol{Age}_{\boldsymbol{j}} + \boldsymbol{\beta}_{\boldsymbol{h}_3} \cdot \boldsymbol{Year}_{\boldsymbol{k}} + \boldsymbol{\beta}_{\boldsymbol{h}_4} \cdot \boldsymbol{Sex}_{\boldsymbol{i}} \cdot \boldsymbol{Age}_{\boldsymbol{j}}$$

With $H_{i,j,k}$ the number of observed AHF hospitalizations (in the SNDS database) during year *k* ($k \in \{2020, 2021, 2022, 2023\}$) in the stratum of persons with sex *i* and age *j* and $\widehat{eH}_{i,j,k}$ the corresponding number of AHF hospitalizations expected to occur with the model during year *k* in the same population stratum.

The resulting difference between observed and expected values is $\widehat{dH}_{i,j,k} = H_{i,j,k} - \widehat{eH}_{i,j,k}$, and the disruption observed year k compared to the expected natural evolution of the number of AHF hospitalizations was calculated as follows:

$$\widehat{dH}_k = \sum_{i \in \{males,\, females\}} \sum_{j=0}^{99} \widehat{dH}_{i,j,k}$$

Similarly, the Poisson regression used for modelling the number of in-hospital deaths among AHF hospitalizations was:

$$\boldsymbol{log}\left(\widehat{\boldsymbol{eM}}_{\boldsymbol{i,j,k}}\right) = \boldsymbol{log}\left(\boldsymbol{H}_{\boldsymbol{i,j,k}}\right) + \boldsymbol{\beta}_{\boldsymbol{m}_0} + \boldsymbol{\beta}_{\boldsymbol{m}_1} \cdot \boldsymbol{Sex}_{\boldsymbol{i}} + \boldsymbol{\beta}_{\boldsymbol{m}_2} \cdot \boldsymbol{Age}_{\boldsymbol{j}} + \boldsymbol{\beta}_{\boldsymbol{m}_3} \cdot \boldsymbol{Year}_{\boldsymbol{k}} + \boldsymbol{\beta}_{\boldsymbol{m}_4} \cdot \boldsymbol{Sex}_{\boldsymbol{i}} \cdot \boldsymbol{Age}_{\boldsymbol{j}}$$

and the disruption observed year *k* compared to the expected natural evolution of the number of in-hospital deaths was calculated as follows:

$$\widehat{dM}_k = \sum_{i \in \{males,\, females\}} \sum_{j=0}^{99} \widehat{dM}_{i,j,k} \qquad \text{with } \widehat{dM}_{i,j,k} = M_{i,j,k} - \widehat{eM}_{i,j,k}$$

All analyses were performed with statistical software R 4.0.2 (R Foundation for Statistical Computing, Vienna, Austria), package ggplot2 was used to generate figures, package stats was used for the general linear model, and 95% confidence intervals (CIs) were estimated over 10,000 bootstrap replications.

Results

Population under study

Between 2013 and 2023, the French population increased from 65.6 million to 68.1 million, and the median age rose from 40 to 42 years (see study flow diagram in Figure 1). During the study period which included a total of 736,954,298 person-years, 2,692,968 AHF hospitalizations occurred at 83 [74; 88] years old (median age [interquartile range]), including 226,771 corresponding in-hospital deaths at 86 [80; 91] years old.

Figure 1: study flow diagram.



In each year-specific cell, **p** corresponds to the population size on January 1 of this given year. Age is reported by its median value [interquartile range], and the percentage of data concerning females is also reported. **h** corresponds to the total number of AHF hospitalizations and **d** to the total number of deaths events that occurred in France each year

Figure 2 presents the number of AHF hospitalizations that occurred each week over the study period, with the corresponding distribution by age and sex. This synthesis picture of exhaustive National data in France over time provides key insights into AHF hospitalization trends. Firstly, hospitalizations predominantly concerned patients aged between 70 and 95 years. Secondly, data present seasonal patterns, with a peak at the beginning of each year and a decrease during summer months. Thirdly, the number of AHF hospitalizations gradually increased from 2013 to 2019. Finally, a sharp decline in hospital admissions was notable during the first wave of the pandemic in April 2020, followed by a series of fluctuations through to 2023, without ever returning to pre-pandemic levels. These visual trends are corroborated by the numerical data in the flow diagram (see Figure 1).

Evolution in the number of AHF hospitalizations

As illustrated in Figure 3A, the numbers of AHF hospitalizations observed in years 2020 to 2023, i.e., after the emergence of the pandemic, consistently remained below the expected numbers based on the trend from the previous seven pre-pandemic years (2013–2019), for both males and females. The decline pattern intensified over time, starting with 39,271 [38,858; 39,688] fewer hospitalizations than expected in 2020, and peaking at 51,573 [51,113; 52,030] fewer in 2023. These estimates correspond to annual reductions ranging from 11.3% to 18.3%. Considering the overall pandemic period, there were 168,518 [167,639; 169,408] fewer AHF hospital admissions, representing a 15.3% reduction from the expected figures. Females were more concerned than males each year, with a total of 91,351 [90,736; 91,949] fewer hospitalizations than expected (16.7%) compared to 77,167 [76,547; 77,794] fewer hospitalizations (13.8%) for males between 2020 and 2023. Detailed annual estimates of the decline in AHF hospitalizations, stratified by sex, are provided in Table 1. As shown in Figure 4, the drop in hospitalizations concerned patients aged 83 [77; 88] years between 2020 and 2023, while the median age of hospitalized patients during the same period was 82 [74; 88] years.

Evolution in the number of in-hospital deaths among AHF hospitalizations

Figure 3B illustrates the evolution of in-hospital mortality among patients hospitalized for AHF in years 2020 to 2023. Throughout the overall pandemic period, in-hospital mortality exceeded expectations for both males and females. This excess mortality steadily increased from 827 [726; 928] excess deaths in 2020 to 2,426 [2,324; 2,530] in 2022, before declining to 1,731 [1,624; 1,838] in 2023. These excess deaths represented relative increases ranging from 4.4% to 13.2% compared to the pre-pandemic trend. The cumulative toll over years 2020 to 2022 reached 6,607 [6,397; 6,818] excess deaths (8.8%). Since 2021, the excess in-hospital mortality concerned more females than males, with corresponding relative increases ranging from 9.6% to 16.0% for females, compared to 7.1% to 11.0% for males. Detailed annual estimates by sex are provided in Table 1. As shown in Figure 5, patients contributing to the excess in-hospital mortality had a median age of 86 years [78; 91], compared to 87 years [80; 91] for those observed.

Figure 2. Occurrences of AHF hospitalizations observed each week in males and females according to age in France, years 2013 to 2023 (N = 2,692,968)



Main panel: Weekly number of AHF hospitalizations according to age. For example, in January 2019, the color gradient is red for individuals aged between 85 and 90, corresponding to a weekly number of around 300 hospitalizations. Top panel: Cumulative numbers (in males and females) of AHF hospitalizations each week in France from 2013 to 2023, broken down by sex. Right panel: Cumulative number (over time) of AHF hospitalizations according to age in males and females.

Figure 3. Differences between observed and expected numbers of AHF hospitalizations (A) and differences between observed and expected numbers of in-hospital deaths (B), France, 2013–2023



*Observed minus expected

A: Main panel, annual difference between observed and expected hospitalizations according to age. For example, in 2023, the color gradient is dark blue for individuals aged 85, corresponding to 1,500 fewer admissions than expected. Top panel, annual cumulative (in males and females) difference between observed and expected hospitalizations, years 2013 to 2019 were used as the reference period. Right panel, cumulative (over time, years 2020 to 2023) difference between observed and expected hospitalizations according to age and sex from.

B: Identical structure of panel A, but applied to in-hospital mortality for AHF hospitalizations.

Table 1: Differences (observed - expected) in the numbers of hospitalizations for acute heart failure, and in the numbers of corresponding in-hospital deaths, France, 2020–2023

	Year			
Difference (observed – expected) *	**2020**	**2021**	**2022**	**2023**
Numbers of hospitalizations	-39,271 [-39,688; -38,858] (-14.5%)	-31,041 [-31,463; -30,611] (-11.3%)	-46,633 [-47,062; -46,191] (-16.8%)	-51,573 [-52,030; -51,113] (-18.3%)
Females	-22,750 [-23,046; -22,460] (-16.9%)	-17,974 [-18,278; -17,677] (-13.3%)	-25,156 [-25,460; -24,841] (-18.4%)	-25,471 [-25,787; -25,148] (-18.5%)
Males	-16,521 [-16,815; -16,225] (-12.1%)	-13,067 [-13,369; -12,758] (-9.4%)	-21,477 [-21,787; -21,166] (-15.3%)	-26,102 [-26,432; -25,772] (-18.2%)
Numbers of in-hospital deaths	827 [726; 928] (4.4%)	1624 [1518; 1732] (8.3%)	2426 [2324; 2530] (13.2%)	1731 [1624; 1838] (9.5%)
Females	402 [332; 471] (4.3%)	933 [858; 1008] (9.6%)	1472 [1400; 1547] (16.0%)	1021 [946; 1097] (11.1%)
Males	425 [352; 498] (4.5%)	691 [615; 768] (7.1%)	954 [880; 1027] (10.4%)	710 [635; 786] (7.9%)

*differences expressed as: mean difference [95% confidence interval] (disruption of the evolution relative to the expected trend, i.e. difference / expected number × 100); reference period for estimating expected numbers = years 2013−2019.

In the first part of the table, the negative difference between observed and expected AHF hospitalizations correspond to a drop in hospitalizations.

In the second part of the table, the positive difference between observed and expected number of deaths correspond to excess mortality during AHF hospitalization.

Figure 4. Population distribution (sex and age) of AHF hospitalizations and estimated drop in hospitalizations, France, 2020–2023.



For each year between 2020 and 2023, an age pyramid represents the observed values for AHF hospitalizations in light gradient and for the estimated drop in hospitalizations in dark gradient. The drop in hospitalizations correspond to the number of hospitalizations missing to reach the expected level based on the pre-pandemic trend. For example, in 2020 (first pyramid), for males (yellow), around 5,000 patients aged 85 years were hospitalized for AHF, about 1,000 fewer than expected based on the pre-pandemic trend.

Figure 5. Population distribution (sex and age) of in hospital deaths during AHF hospitalizations and estimated excess mortality, France, 2020–2023.



For each year between 2020 and 2023, an age pyramid represents the observed values for deaths during AHF hospitalizations in light gradient and for the estimated excess deaths in dark gradient. The excess deaths correspond to the number of deaths in excess over the expected level based on the pre-pandemic trend. For example, in 2022, 700 females aged 90 years died during AHF hospitalization, about 100 more than expected based on the pre-pandemic trend.

Discussion

Key results

In this open cohort study of the French population from 2013 to 2023 (736,954,298 person-years), trends in AHF hospitalizations and corresponding in-hospital mortality were analyzed to accurately quantify the extent of disruption during the COVID-19 pandemic period (2020–2023). A major and prolonged disruption has been highlighted since the onset of the pandemic, and it continues to persist as of 2023. Specifically, a substantial decline of 14.5% in hospital admissions occurred in 2020, and surprisingly, this decline increased to 18.3% in 2023. The decline, observed all over the pandemic period, concerned both sexes but was more pronounced in females. As shown in Figure 4, the decline in hospitalizations was more pronounced among older patients. This trend is further supported by the flow diagram, which illustrates that the median age of hospitalized patients increased from 2013 to 2019, reflecting the aging population in France. However, during the pandemic period, a decrease in the median age of patients hospitalized for AHF was observed, indicating that the decline in hospitalizations particularly affected the oldest patients. As shown in Supplementary Analysis 3, the decline in hospitalizations appears to be specific to AHF. Indeed, while the healthcare system experienced global disruptions since 2020, the reduction in hospitalizations was even more pronounced in AHF patients compared to the general population, and this gap widened over time (Supplementary Figure 5, Supplementary Table 3).

In contrast to the decline in AHF hospitalizations, in-hospital mortality exceeded expectations, with excess mortality ranging from 4.4% to 13.2% between 2020 and 2023. This corresponded to an estimated total of 6,607 [6,397; 6,818] excess in-hospital deaths, representing an 8.8% increase compared to the expected mortality based on the pre-pandemic trend. Similar to the decline in hospital admissions, the increase in hospital mortality affected both sexes throughout the pandemic and was more pronounced in females. As shown in Figure 5, this increase in in-hospital mortality did not only affect the oldest patients.

Interpretation

The study confirms previous national observations regarding the decline in AHF hospitalizations between 2020 and 2022, while providing more detailed insights into the magnitude of the disruption. Additionally, it extends the analysis to include 2023, offering a comprehensive assessment of the pandemic period's long-term impact thanks to nationwide data spanning 11 consecutive years. The drop in hospitalizations, ranging from 11.3% to 14.5% in 2020 and 2021, aligns with figures reported in Europe[7,8] and worldwide.[9–11] Importantly, while it was anticipated that after the widespread vaccination against Covid-19, and the reduction in pandemic severity in 2022 and 2023, the situation would return to the pre-pandemic state, the study evidenced that the disruption worsened in the following years, peaking at 18.3% fewer hospitalizations in 2023.

Two contrasting effects of the pandemic may have contributed to the substantial decline in AHF hospitalizations. Firstly, a series of protective effects related to the pandemic period could have led to a reduction in AHF incidence and, consequently, fewer hospitalizations. Key changes in population behaviors since 2020, such as widespread mask usage, reduced the transmission of respiratory viruses, which are well-known to increase the risk of acute decompensation in AHF patients.[32,33] Shifts in healthcare practices, including the rapid expansion of telemedicine,[34,35] the introduction of new medications,[36] and major initiatives by the National Health Insurance since 2022,[37] may have improved patient care and further contributed to the reduction in hospitalizations for AHF. While these factors likely explain part of the decrease in hospitalizations, they do not fully account for the abrupt and persistent nature of this change, nor do they clarify why older individuals and females have been particularly concerned.

Secondly, a series of detrimental effects from the pandemic may have led to premature deaths before hospitalization, thus reducing the overall number of hospitalizations. The widespread impact of the pandemic period resulted in a sudden and prolonged period of excess mortality in France,[38,39] which is consistent with the observed decline in hospital admissions for years 2020 to 2022. The major risk factors for COVID-19 mortality, such as older age and comorbidities,[40] closely match the profile of patients typically hospitalized for AHF. However, this direct effect of the pandemic cannot fully explain the decrease in AHF hospitalizations. COVID-19-related deaths officially decreased from 69,000 in 2020[41] to 5,572 in 2023,[42] while the present study results indicate that decline in the number of AHF hospitalizations was 39,271 fewer admissions in 2020, and peaked in 2023 with 51,573 fewer admissions. Beyond direct competitive effects, some negative indirect consequences of the pandemic may also have contributed to premature death.[43] Factors such as fear of seeking hospital care, or reduction of the initiation of medication treatments for cardiovascular risk documented in France in 2020[44] may have led to out-of-hospital AHF-related deaths before hospitalization. Indeed, studies have reported a significant increase in out-of-hospital AHF-related deaths occurring at home during 2020, with rises ranging from 25% to 35% compared to the pre-pandemic period.[45,46] Numerous studies have documented gender inequality in the management of cardiovascular care,[47–49] making it likely that, during a crisis, females were among the first to suffer the negative consequences. Notably, a rise in cardiovascular mortality was observed in France from 2020 to 2022, particularly among females.[50]

Study results indicate that in-hospital deaths among AHF hospitalizations exceeded expected levels throughout the pandemic. While some previous studies found no significant change in in-hospital mortality,[12–14] others reported an increase.[15–17] These discrepancies may be due to differences between countries or to the greater statistical power provided by the exhaustive data used in the present study. The increase in in-hospital mortality during the early phase of the pandemic could be attributed to COVID-19-related deaths. In 2020, for instance, 929 AHF-hospitalized patients died of COVID-19, potentially explaining the 827 excess deaths estimated for that year (Supplementary Table 2). However, COVID-19 mortality among AHF patients predominantly affected males and has declined over time. In contrast, in-hospital excess mortality has risen, particularly among females. Notably, in 2022, COVID-19 mortality could account for only 27% of the excess in hospital mortality observed in females. While COVID-19-related mortality, as a new cause of death emerging in 2020, could have explained the increase in in-hospital mortality among AHF patients, this is not consistent with the worsening mortality over time, nor with the disproportionate impact on females. A reduction in hospital capacity in France,[51] which has worsened since the start of the pandemic, may have restricted hospitalizations to the most severe cases, thereby increasing in-hospital mortality rates. The persistent excess mortality observed in this study is concerning and suggests a profound and long-lasting disruption in the healthcare system's ability to manage AHF patients, particularly females.

Strengths & limitations

This study has two major strengths, it is based on the exhaustive data of AHF hospitalizations in France, and it covers the complete pandemic period. The evolving patterns reported are reliably representative of the whole country. Moreover, analyses include seven years of pre-pandemic data, allowing to take into account the historical trends before the emergence of the pandemic, and to provide reliable estimates of the subsequent perturbations. Most studies published to date have shorter reference periods and/or only estimate disruptions for parts of the pandemic. This study not only offers detailed results on the decline in hospital admissions and the increase in hospital mortality by year, sex, and age, but also documents the evolution of these indicators over 11 consecutive years at the national level.

This study has several limitations. Patient identification is based on ICD-10 codes, which are susceptible to coding errors. Important confounding factors such as weight, tobacco use, blood pressure, and clinical information such as biological or radiological results were not included in the analysis. This is because the database, being primarily administrative, does not yet incorporate clinical data. Additionally, as healthcare systems vary between countries, the findings of this national study cannot be directly generalized to other nations. However, as previously mentioned, similar patterns have been reported in studies conducted elsewhere. Several hypotheses were proposed regarding the impact of the COVID-19 pandemic on AHF hospitalizations and mortality. These include both protective and negative effects, direct impacts on mortality, and indirect disruptions to the healthcare system. However, due to the complexity and multifactorial nature of these causes, it is not possible to draw causal conclusions. Nevertheless, one thing is clear: a major disruption in the management of AHF patients occurred at the onset of the pandemic and continues to persist into 2023.

Conclusion

This study reveals significant disruptions in the healthcare pathway for AHF, marked by a decline in hospitalizations and an increase in in-hospital mortality from the onset of the COVID-19 pandemic in 2020 through to 2023, with a particular impact on females. Further research devoted to explore the underlying causes of these persistent disruptions is of primary importance for developing strategies to mitigate their impact.

Funding
This work was supported by the Initiative Économie de la Santé of Sorbonne Université (Idex Sorbonne Université, programmes Investissements d'Avenir), and by the Ministère de la Solidarité et de la Santé (Programme de Recherche sur la Performance du Système des Soins, PREPS 20-0163). The sponsor and the funders had no role in study design, data collection and analysis, interpretation of data, decision to publish, or preparation of the manuscript.

Disclosure of interest
The authors of this manuscript have no conflict of interest to disclose.

Data availability statement
According to the principles of data protection and French regulations, the authors cannot publicly release the data from the French National Health Data System (SNDS). However, any person or structure, public or private, for-profit or non-profit, can access SNDS data upon authorization from the French Data Protection Office (CNIL, Commission Nationale de l'Informatique et des Libertés) to carry out a study, research, or an evaluation of public interest (https://www.snds.gouv.fr/SNDS/Contexte-et-perspectives-reglementaires#).

Notes
The COVID-HOSP study group: Tristan Delory (Centre Hospitalier Annecy Genevois, Annecy, France); Fanny Duchaine (IRDES, Paris, France); Maude Espagnacq (IRDES, Paris, France); Gilles Hejblum (INSERM, Paris, France); Myriam Khlat (INED, Aubervilliers, France); Nathanaël Lapidus (INSERM, Paris, France); Sophie Le Cœur (INED, Aubervilliers, France); Elhadji Leye (INSERM, Paris, France); Paul Moulaire (INSERM, Paris FRANCE); Jonas Poucineau (INED, Aubervilliers, France).

References

1. Maxmen A. Wuhan market was epicentre of pandemic's start, studies suggest. *Nature* 2022;**603**:15–16.

2. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov) (11 September 2024)

3. Hsiang S, Allen D, Annan-Phan S, Bell K, Bolliger I, Chong T, Druckenmiller H, Huang LY, Hultgren A, Krasovich E, Lau P, Lee J, Rolf E, Tseng J, Wu T. The effect of large-scale anti-contagion policies on the COVID-19 pandemic. *Nature* 2020;**584**:262–267.

4. Tuppin P, Lesuffleur T, Constantinou P, Atramont A, Coatsaliou C, Ferrat E, Canouï-Poitrine F, Debeugny G, Rachas A. Underuse of primary healthcare in France during the COVID-19 epidemic in 2020 according to individual characteristics: a national observational study. *BMC Prim Care* 2022;**23**:200.

5. Huet F, Prieur C, Schurtz G, Gerbaud E, Manzo-Silberman S, Vanzetto G, Elbaz M, Tea V, Mercier G, Lattuca B, Duflos C, Roubille F. One train may hide another: Acute cardiovascular diseases could be neglected because of the COVID-19 pandemic. *Arch Cardiovasc Dis* 2020;**113**:303–307.

6. Olié V, Isnard R, Pousset F, Grave C, Blacher J, Gabet A. Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022. *ESC Heart Fail* **n/a**.

7. Khan Y, Verhaeghe N, Devleesschauwer B, Cavillot L, Gadeyne S, Pauwels N, Van den Borre L, De Smedt D. The impact of the COVID-19 pandemic on delayed care of cardiovascular diseases in Europe: a systematic review. *Eur Heart J - Qual Care Clin Outcomes* 2023;**9**:647–661.

8. Cannata A, Watson SA, Daniel A, Giacca M, Shah AM, McDonagh TA, Scott PA, Bromage DI. Impact of the COVID-19 pandemic on in-hospital mortality in cardiovascular disease: a meta-analysis. *Eur J Prev Cardiol* 2021;**29**:1266–1274.

9. Fox DK, Waken RJ, Johnson DY, Hammond G, Yu J, Fanous E, Maddox TM, Joynt Maddox KE. Impact of the COVID-19 Pandemic on Patients Without COVID-19 With Acute Myocardial Infarction and Heart Failure. *J Am Heart Assoc* 2022;**11**:e022625.

10. Jayagopa PB, Ramakrishnan S, Mohanan PP, Jabir A, Venugopal K, Das MK, Santhosh K, Syam N, Ezhilan J, Agarwal R, Vaidyanathan PR, Choudhary AH, Meena CB, Malviya A, Gopi A, Chopra VK, Joseph S, Goyal KK, John JF, Bansal S, Harikrishnan S, Nagula P, Joseph J, Bagawat A, Seth S, Shah U, Goel PK, Asokan PK, Sethi KK, Sharma S, Banerji A, Sikdar S, Agarwala M, Chandra S, Bharti B, Ashraf SM, Srivastava S, Kesavamoorthy B, Bali HK, Sarma D, Jain RK, Dani SI, Natesh BH, Chakraborty RN, Gupta V, Khanna NN, Mukhopadhyay D, Mandal S, Majumder B, Sridhar L, Girish MP, Das D, Devasia T, Vajifdar B, Bhatia T, Abdullah Z, Sharma S, Kumar S, Lincy M, Naik N, Kahali D, Sinha DP, Dastidar DG, Wander GS, Yadav R, Tewari S, Bhandari S, Rath PC, Bang VH, Roy D, Banerjee P, Shanmugasundaram S, Zachariah G. Impact of COVID-19 on heart failure hospitalization and outcome in India - A cardiological society of India study (CSI-HF in COVID 19 times study - 'The COVID C-HF study'). *INDIAN HEART J* 2023;**75**:370–375.

11. Seidu S, Kunutsor SK, Cos X, Khunti K. Indirect impact of the COVID-19 pandemic on hospitalisations for cardiometabolic conditions and their management: A systematic review. *Prim Care Diabetes* 2021;**15**:653–681.

12. Cannatà A, Bromage DI, Rind IA, Gregorio C, Bannister C, Albarjas M, Piper S, Shah AM, McDonagh TA. Temporal trends in decompensated heart failure and outcomes during COVID-19: a multisite report from heart failure referral centres in London. *Eur J Heart Fail* 2020;**22**:2219–2224.

13. König S, Hohenstein S, Meier-Hellmann A, Kuhlen R, Hindricks G, Bollmann A, Helios Hospitals, Germany. In-hospital care in acute heart failure during the COVID-19 pandemic: insights from the German-wide Helios hospital network. *Eur J Heart Fail* 2020;**22**:2190–2201.

14. Kubica J, Ostrowska M, Stolarek W, Kasprzak M, Grzelakowska K, Kryś J, Kubica A, Adamski P, Podhajski P, Navarese EP, Anielska-Michalak E, Brycht O, Curzytek A, Dudek A, Gromadziński L, Grzelakowski P, Kamiński L, Kleinrok A, Kostkiewicz M, Koziński M, Król P, Kulawik T, Minczew G, Mindykowski M, Pawlak A, Prokopczuk J, Skonieczny G, Sobkowicz B, Sowiński S, Stankala S, Szymański P, Wester A, Wilczewski P, Bartuś S, Budaj A, Gąsior M, Gruchała M, Drożdż J, Jaguszewski M, Jankowski P, Legutko J, Lesiak M, Leszek P, Mitkowski P, Nessler J, Tomaszuk-Kazberuk A, Tycińska A, Zdrojewski T, Kaźmierczak J. Impact of COVID-19 pandemic on acute heart failure admissions and mortality: a multicentre study (COV-HF-SIRIO 6 study). *ESC Heart Fail* 2022;**9**:721–728.

15. Wang SY, Seghieri C, Vainieri M, Groene O. Changes in Acute Myocardial Infarction, Stroke, and Heart Failure Hospitalizations During COVID-19 Pandemic in Tuscany-An Interrupted Time Series Study. *Int J Public Health* 2022;**67**:1604319.

16. Andersson C, Gerds T, Fosbøl E, Phelps M, Andersen J, Lamberts M, Holt A, Butt JH, Madelaire C, Gislason G, Torp-Pedersen C, Køber L, Schou M. Incidence of New-Onset and Worsening Heart Failure Before and After the COVID-19 Epidemic Lockdown in Denmark: A Nationwide Cohort Study. *Circ Heart Fail* 2020;**13**:e007274.

17. Cedrone F, Di Martino G, Di Giovanni P, Greco E, Trebbi E, Romano F, Staniscia T. Reduction in Hospital Admissions for Cardiovascular Diseases (CVDs) during the Coronavirus Disease 2019 (COVID-19) Pandemic: A Retrospective Study from a Southern Italian Region in the Year 2020. *Healthcare* 2022;**10**:871.

18. Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemichttps://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic (28 June 2024)

19. Tuppin P, Rudant J, Constantinou P, Gastaldi-Menager C, Rachas A, Roquefeuil L de, Maura G, Caillol H, Tajahmady A, Coste J, Gissot C, Weill A, Fagot-Campagna A. Value of a national administrative database to guide public decisions: From the systeme national d'information interregimes de l'Assurance Maladie (SNIIRAM) to the systeme national des donnees de sante (SNDS) in France. *Rev Epidemiol Sante Publique* 2017;**65**:S149–S167.

20. Grave C, Gabet A, Puymirat E, Empana J-P, Tuppin P, Danchin N, Olié V. Myocardial infarction throughout 1 year of the COVID-19 pandemic: French nationwide study of hospitalization rates, prognosis and 90-day mortality rates. *Arch Cardiovasc Dis* 2021;**114**:768–780.

21. Gabet A, Grave C, Tuppin P, Emmerich J, Olié V. Changes in the epidemiology of patients hospitalized in France with deep venous thrombosis and pulmonary embolism during the COVID-19 pandemic. *Thromb Res* 2021;**207**:67–74.

22. Gabet A, Grave C, Tuppin P, Chatignoux E, Béjot Y, Olié V. Impact of the COVID-19 pandemic and a national lockdown on hospitalizations for stroke and related 30-day mortality in France: A nationwide observational study. *Eur J Neurol* 2021;**28**:3279–3288.

23. Leye E, Delory T, El Karoui K, Espagnacq M, Khlat M, Le Coeur S, Lapidus N, Hejblum G. Direct and indirect impact of the COVID-19 pandemic on the survival of kidney transplant recipients: A national observational study in France. *Am J Transplant* 2024;**24**:479–490.

24. Poucineau J, Khlat M, Lapidus N, Espagnacq M, Chouaïd C, Delory T, Le Coeur S. Impact of the COVID-19 Pandemic on COPD Patient Mortality: A Nationwide Study in France. *Int J Public Health* 2024;**69**:1606617.

25. Institut national de la statistique et des études économiques (French National Institute of Statistics and Economic Studies). Séries Population et structure de la population | Inseehttps://www.insee.fr/fr/statistiques/series/103088458 (18 September 2024)

26. Vandenbroucke JP, Elm E von, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M, Initiative for the S. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. *PLOS Med* 2007;**4**:e297.

27. Heidari S, Babor TF, De Castro P, Tort S, Curno M. Sex and Gender Equity in Research: rationale for the SAGER guidelines and recommended use. *Res Integr Peer Rev* 2016;**1**:2.

28. Méthodehttps://www.assurance-maladie.ameli.fr/etudes-et-donnees/par-theme/pathologies/cartographie-assurance-maladie/methode-cartographie-pathologies-depenses-assurance-maladie (20 September 2024)

29. Alicandro G, La Vecchia C, Islam N, Pizzato M. A comprehensive analysis of all-cause and cause-specific excess deaths in 30 countries during 2020. *Eur J Epidemiol* 2023;**38**:1153–1164.

30. Barnard S, Chiavenna C, Fox S, Charlett A, Waller Z, Andrews N, Goldblatt P, Burton P, De Angelis D. Methods for modelling excess mortality across England during the COVID-19 pandemic. *Stat Methods Med Res* 2022;**31**:1790–1802.

31. Fantin R, Barboza-Solís C, Hildesheim A, Herrero R. Excess mortality from COVID 19 in Costa Rica: a registry based study using Poisson regression. *Lancet Reg Health – Am* 2023;**20**.

32. Girerd N, Chapet N, Roubille C, Roncalli J, Salvat M, Mouquet F, Lamblin N, Gueffet J-P, Damy T, Galinier M, Tartiere J-M, Janssen C, Berthelot E, Aguilhon S, Escamilla R, Roubille F. Vaccination for Respiratory Infections in Patients with Heart Failure. *J Clin Med* 2021;**10**:4311.

33. Alon D, Stein GY, Korenfeld R, Fuchs S. Predictors and Outcomes of Infection-Related Hospital Admissions of Heart Failure Patients. *PLOS ONE* 2013;**8**:e72476.

34. Berthelot E, Flécher E, Roubille F, Damy T, Lamblin N. Impact of the COVID-19 pandemic on the burden of chronic heart failure patients in France. *Ann Cardiol Angéiologie* 2021;**70**:191–195.

35. Severino P, Prosperi S, D'Amato A, Cestiè C, Myftari V, Maestrini V, Birtolo LI, Filomena D, Mariani MV, Lavalle C, Badagliacca R, Mancone M, Fedele F, Vizza CD. Telemedicine: an

Effective and Low-Cost Lesson From the COVID-19 Pandemic for the Management of Heart Failure Patients. *Curr Heart Fail Rep* 2023;**20**:382–389.

36. BrJCardiol. Drug therapy in heart failure – an update from the 2021 ESC heart failure guidelinehttps://bjcardio.co.uk/2022/07/drug-therapy-in-heart-failure-an-update-from-the-2021-esc-heart-failure-guideline/ (19 September 2024)

37. Campagne insuffisance cardiaquehttps://www.assurance-maladie.ameli.fr/qui-sommes-nous/action/campagnes-communication/campagne-insuffisancecardiaque (17 September 2024)

38. Blanpain N. 53,800 more deaths than expected in 2022: higher excess mortality than in 2020 and 2021. Insee Première. 2023; 1951https://www.insee.fr/en/statistiques/7635866 (19 September 2024)

39. Moulaire P, Hejblum G, Lapidus N. Excess mortality and years of life lost from 2020 to 2023 in France: a cohort study of the overall impact of the COVID-19 pandemic on mortality. *BMJ Public Health* 2025;**3**.

40. Semenzato L, Botton J, Drouin J, Cuenot F, Dray-Spira R, Weill A, Zureik M. Chronic diseases, health conditions and risk of COVID-19-related hospitalization and in-hospital mortality during the first wave of the epidemic in France: a cohort study of 66 million people. *Lancet Reg Health - Eur* 2021;**8**:100158.

41. Naouri D. COVID-19: third leading cause of death in France in 2020, while other major causes of death decline. Études et Résultats. 2022 Dec;1250:1–7https://drees.solidarites-sante.gouv.fr/publications-en-anglais/covid-19-third-leading-cause-death-france-2020-while-other-major-causes (19 September 2024)

42. COVID-19 Data Explorer. *Our World in Data*. https://ourworldindata.org/explorers/covid (19 September 2024)

43. McAlister FA, Parikh H, Lee DS, Wijeysundera HC. Health Care Implications of the COVID-19 Pandemic for the Cardiovascular Practitioner. *Can J Cardiol* 2023;**39**:716–725.

44. Gabet A, Grave C, Tuppin P, Lesuffleur T, Guenancia C, Nguyen-Thanh V, Guignard R, Blacher J, Olié V. Nationwide Initiation of Cardiovascular Risk Treatments During the COVID-19 Pandemic in France: Women on a Slippery Slope? *Front Cardiovasc Med* 2022;**9**.

45. Wu J, Mamas MA, Mohamed MO, Kwok CS, Roebuck C, Humberstone B, Denwood T, Luescher T, Belder MA de, Deanfield JE, Gale CP. Place and causes of acute cardiovascular mortality during the COVID-19 pandemic. *Heart* 2021;**107**:113–119.

46. Shoaib A, Van Spall HGC, Wu J, Cleland JGF, McDonagh TA, Rashid M, Mohamed MO, Ahmed FZ, Deanfield J, Belder M de, Gale CP, Mamas MA. Substantial decline in hospital admissions for heart failure accompanied by increased community mortality during COVID-19 pandemic. *Eur Heart J Qual Care Clin Outcomes* 2021;**7**:378–387.

47. Betai D, Ahmed AS, Saxena P, Rashid H, Patel H, Shahzadi A, Mowo-wale AG, Nazir Z, Betai D, Ahmed AS, Saxena P, Rashid H, Patel H, Shahzadi A, Mowo-wale AG, Nazir Z. Gender Disparities in Cardiovascular Disease and Their Management: A Review. *Cureus* 2024;**16**.

48. López Ferreruela I, Obón Azuara B, Malo Fumanal S, Rabanaque Hernández MJ, Aguilar-Palacio I. Gender inequalities in secondary prevention of cardiovascular disease: a scoping review. *Int J Equity Health* 2024;**23**:146.

49. Grave C, Gabet A, Cinaud A, Tuppin P, Blacher J, Olié V. Nationwide time trends in patients hospitalized for acute coronary syndrome: a worrying generational and social effect among women. *Eur J Prev Cardiol* 2024;**31**:116–127.

50. Fouillet A, Cadillac M, Riviera C, Coudin E. Leading causes of death in France in 2022 and recent trends. *Bull Épidémiol Hebd. 2024;(18):388-411.* http://beh.santepubliquefrance.fr/beh/2024/18/2024_18_1.html (10 October 2024)

51. Boisguérin B, Gaimar L. En 2022, la baisse du nombre de lits en état d'accueillir des patients s'accentue | Direction de la recherche, des études, de l'évaluation et des statistiqueshttps://drees.solidarites-sante.gouv.fr/publications-communique-de-presse/etudes-et-resultats/en-2022-la-baisse-du-nombre-de-lits-en-etat (6 January 2025)